Clinical trials: Reduction of Inflammation
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02235272
- Testing
- XG-102
- Where
- United States
- Volunteers
- 339 people
- Sponsor
- Xigen SA
Elective Cardiac Surgery
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.
- Trial name
- REFRESH (NCT02566525)
- Testing
- CytoSorb
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- CytoSorbents, Inc
Full-thickness Skin Defects, Degloving Injuries
RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
A prospective randomized within-subject controlled study to compare the clinical performance of conventional autografting with and without the RECELL system on acute non-burn full-thickness skin defects.
- Conditions
- Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin
- Trial name
- NCT04091672
- Testing
- Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- Avita Medical
HIV Infections, Dyslipidemias
Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)
This is a phase 2, randomized, double-blinded, placebo-controlled clinical trial. The intervention drug will be efprezimod alfa (intravenous [IV] infusion).
- Trial name
- CALIBER (NCT03960541)
- Testing
- Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Thrombosis, Deep Vein, Iliofemoral; Thrombosis
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate…
- Trial name
- DEXTERITY-AFP (NCT04862468)
- Testing
- Perivascular dexamethasone
- Where
- 22 sites in United States, Ireland and 1 more
- Volunteers
- 80 people
- Sponsor
- Mercator MedSystems, Inc.
Septicemia
Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device When Collected Through Peripheral Intravenous Catheters
This is a randomized, open label study to evaluate the Initial Specimen Diversion Device (ISDD) in reducing the contamination rate in blood culture analysis.
- Trial name
- NCT02093494
- Testing
- Initial Specimen Diversion Device (ISDD), Lab standard practice (LSP), Peripheral Intravenous Catheters (PIVC)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Magnolia Medical Technologies, Inc.
Low Gelsolin, Trauma
Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels
This study is designed to assess the pharmacokinetics and safety of an infusion of a single dose of recombinant plasma gelsolin (rhu-pGelsolin) when given to patients admitted to the Intensive Care Unit with documented low levels…
- Conditions
- Low Gelsolin, Trauma, Infection, Burns
- Trial name
- NCT00671307
- Testing
- rhu-pGelsolin
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Critical Biologics Corporation
Resolution of Inflammation, Reduction of Cell Proliferation
Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride…
- Trial name
- PBMC (NCT05161702)
- Testing
- MAG-SPM treatment on isolated PBMC cells, Isolated PBMC cells without treatment.
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- SCF Pharma
Sepsis, Respiratory Failure
Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of…
- Trial name
- NUC-CAP (NCT05647096)
- Testing
- NucleoCapture device
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 73 people
- Sponsor
- Santersus AG
SARS-CoV-2
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the…
- Trial name
- NCT04324021
- Testing
- Emapalumab, Anakinra
- Where
- 12 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Swedish Orphan Biovitrum
Heart Failure, Systemic Inflammation
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks…
- Trial name
- ATHENA (NCT06200207)
- Testing
- Ziltivekimab
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 673 people
- Sponsor
- Novo Nordisk A/S
Sepsis, Adult Disease
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Baylor S&W
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in…
- Conditions
- Sepsis, Adult Disease, Emergency Department, Severe Sepsis
- Trial name
- NCT04291417
- Testing
- CBC-DIFF Monocyte Volume Width Distribution (MDW)
- Where
- United States
- Volunteers
- 1,700 people
- Sponsor
- Beckman Coulter, Inc.
Plaque, Gingivitis
A Clinical Trial to Test the Effect of Marketed Mouth Rinses on Decreasing Plaque and Gum Inflammation
The reduction of existing plaque and gum inflammation will be evaluated using two marketed mouth rinses along with tooth brushing after 21 days of use compared to a placebo mouth rinse.
- Trial name
- NCT02233998
- Testing
- Mouth Rinse 1, Mouth Rinse 2, Mouth Rinse 3
- Where
- Canada
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02508337
- Testing
- XG-102
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- Xigen SA
Inflammation, Oxidative Stress
Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking
This is a cross-sectional 3-group study with subjects enrolled and matched by region (Asia, Europe), age, sex, and average daily product consumption over the last 2 years as self-reported.
- Conditions
- Inflammation, Oxidative Stress, Smoking, Smoking Abstinence
- Trial name
- NCT05385055
- Testing
- THS use, Cigarette smoking, Smoking abstinence
- Where
- 37 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 974 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid…
- Trial name
- PREDICTRA (NCT02198651)
- Testing
- Adalimumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 149 people
- Sponsor
- AbbVie
Gingival Inflammation, Plaque
Stannous Fluoride Toothpaste for Reduction and Treatment of Gingivitis
This study evaluated the efficacy of a stannous fluoride toothpaste compared to a sodium fluoride control toothpaste in reducing gingivitis, bleeding, and plaque over a 12-week period.
- Conditions
- Gingival Inflammation, Plaque, Bleeding
- Trial name
- NCT07640399
- Testing
- Sodium Fluoride Dentifrice, Stannous Fluoride Toothpaste (SnF)
- Where
- Canada
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Church & Dwight Company, Inc.
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Septicemia
Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device
This is a matched, open label study to evaluate the Initial Specimen Diversion Device (ISDD) in reducing the contamination rate in blood culture analysis.
- Trial name
- NCT02102087
- Testing
- Initial Specimen Diversion Device (ISDD), Lab standard practice (LSP)
- Where
- United States
- Volunteers
- 971 people
- Sponsor
- Magnolia Medical Technologies, Inc.
Sarcopenia in Elderly, Frailty
Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness.
- Conditions
- Sarcopenia in Elderly, Frailty, Frailty/Sarcopenia, Frailty in Older Adults
- Trial name
- NCT06942182
- Testing
- Isomyosamine 250mg
- Volunteers
- 60 people
- Sponsor
- TNF Pharmaceuticals, Inc.